TJ-M2010-5 binds to the MyD88 TIR domain, blocks TLR/MyD88 signaling, and plays a significant role in reducing inflammatory effects and liver fibrosis [97], alleviating organ ischemia/reperfusion injury [98], preventing colitis-associated colorectal cancer [99], combating hepatocellular carcinoma [100], reducing allogeneic rejection [101], and enhancing allogeneic transplantation tolerance [102]. Here, MYD88 is linked to colitis.